Vortioxetine: Difference between revisions

Vortioxetine is used as a treatment for [[major depressive disorder]].<ref name=AHFS2019/> Effectiveness appears to be similar to other [[antidepressants]]<ref name=AHFS2019/><ref name="Long 2019 pp. 819–820">{{cite journal | vauthors = Long JD | title = Vortioxetine for Depression in Adults | journal = Issues in Mental Health Nursing | volume = 40 | issue = 9 | pages = 819–820 | date = September 2019 | pmid = 31225773 | doi = 10.1080/01612840.2019.1604920 | publisher = Informa UK Limited | s2cid = 195192772 }}</ref><ref name="pmid29477251">{{cite journal | vauthors = Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JP, Geddes JR | title = Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis | journal = Lancet | volume = 391 | issue = 10128 | pages = 1357–1366 | date = April 2018 | pmid = 29477251 | pmc = 5889788 | doi = 10.1016/S0140-6736(17)32802-7 | url = }}</ref> and in terms ofits [[effect size]] has been described as modest.<ref name="pmid28499187">{{cite journal | vauthors = Sowa-Kućma M, Pańczyszyn-Trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M | title = Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant | journal = Pharmacol Rep | volume = 69 | issue = 4 | pages = 595–601 | date = August 2017 | pmid = 28499187 | doi = 10.1016/j.pharep.2017.01.030 | s2cid = 43104089 | url = }}</ref> Vortioxetine may be used when other treatments have failed.<ref name="Trintellix FDA label" /><ref>{{cite journal | vauthors = Connolly KR, Thase ME | title = Vortioxetine: a New Treatment for Major Depressive Disorder | journal = Expert Opinion on Pharmacotherapy | volume = 17 | issue = 3 | pages = 421–31 | date = 2016 | pmid = 26679430 | doi = 10.1517/14656566.2016.1133588 | quote = The authors suggest that vortioxetine is currently a good second-line antidepressant option and shows promise, pending additional long-term data, to become a first-line antidepressant option. | s2cid = 40432194 }}</ref><ref>{{cite journal | vauthors = Köhler S, Cierpinsky K, Kronenberg G, Adli M | title = The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants | journal = Journal of Psychopharmacology | volume = 30 | issue = 1 | pages = 13–22 | date = January 2016 | pmid = 26464458 | doi = 10.1177/0269881115609072 | s2cid = 21501578 }}</ref><ref name=KellinyRev2015>{{cite journal | vauthors = Kelliny M, Croarkin PE, Moore KM, Bobo WV | title = Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature | journal = Therapeutics and Clinical Risk Management | volume = 11 | pages = 1193–212 | year = 2015 | pmid = 26316764 | pmc = 4542474 | doi = 10.2147/TCRM.S55313 | doi-access = free | title-link = doi }}</ref> A 2017 [[Cochrane (organisation)|Cochrane]] review on vortioxetine determined that the place for it in the treatment of severe depression is unclear due to low-quality evidence and that more study is needed comparing vortioxetine to [[selective serotonin reuptake inhibitor]]s (SSRIs) which are typical first-line treatments.<ref>{{cite journal | vauthors = Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C | title = Vortioxetine for depression in adults | journal = The Cochrane Database of Systematic Reviews | volume = 2017 | pages = CD011520 | date = July 2017 | issue = 7 | pmid = 28677828 | pmc = 6483322 | doi = 10.1002/14651858.CD011520.pub2 }}</ref> Vortioxetine appears to work in depressed patients with anxiety.<ref>{{cite journal | vauthors = Mattingly GW, Ren H, Christensen MC, Katzman MA, Polosan M, Simonsen K, Hammer-Helmich L | title = Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study | journal = Frontiers in Psychiatry | volume = 13 | pages = 824831 | date = 2022 | pmid = 35356713 | doi = 10.3389/fpsyt.2022.824831 | pmc = 8959350 | doi-access = free }}</ref>